Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2013-2017

ABSTRACT

The purpose of this study is to determine if the drug Plerixafor (Mozobil) can lead to clinically relevant efflux of CD117+ stem cells from the bone marrow to the peripheral blood of normal controls and patients awaiting lung transplantation. The investigator's hypothesis is that Plerixafor (Mozobil) will lead to significant mobilization of CD117+ stem cells to the peripheral blood. Detailed Description The investigators have developed a new therapy utilizing a stem cell found in the bone marrow that is defined by cell surface expression of the protein "cluster of differentiation antigen 117" (CD117). Studies utilizing these stem cells in a mouse heart transplant model have demonstrated significantly improved survival of transplanted hearts, (as much as more than 5 times that seen with untreated heart transplants). In vitro studies in mice also show that these cells work to inhibit the immune system by inhibiting T cell activation/proliferation by both paracrine (primary) and contact-dependent (lesser) mechanisms. Importantly, these stem cells are taken from the intended transplant recipient (autologous) and since these cells are part of their own body normally (in small numbers); these cells are theoretically without risk to the patient. This is very different from other stem cell therapies, which are taken from the donor and as such put the patient at significant risk of developing potentially life-threatening immune reactions. Because the use of our own stem cells is potentially safe - the rapid study, development, and implementation of autologous CD117 stem cell (SC) therapy in human transplant patients is theoretically possible. Therefore, these cells have high impact potential for the field of tissue and organ transplantation as well as auto-immunity - to potentially improve tissue/cellular engraftment, decrease acute rejection, and/or to promote organ transplant tolerance (lack of rejection despite no concomitant immune-suppression). Prior to full clinical development (efficacy trials in humans), the next step is to develop a safe and efficacious means for obtaining relatively large quantities of these cells from potential human recipients. As bone marrow biopsy for cell capture is not without risk (especially to ill potential lung transplant recipients), the investigators propose to use Plerixafor (Mozobil), a CXC-chemokine receptor 4 (CXCR4)-inhibitor to cause efflux of bone marrow-derived CD117+ cells to the peripheral blood for capture by apheresis/positive selection. If successful, the next step will be to perform initial safety studies in human patients awaiting transplantation and normal controls (not a goal of this initial protocol however). These studies have the potential to lead to large-scale clinical efficacy trials and ultimate indication/implementation for human disease(s). Primary Outcome Measure: The number of circulating CD117+ cells per milliliter (ml) of peripheral blood at baseline and following Plerixafor (Mozobil) treatment (change in peripheral blood CD117+ cells per ml). Secondary Outcome Measures: i.) The number of Plerixafor (Mozobil) related adverse events (AEs). ii.) The number of patients with Plerixafor (Mozobil) related AEs iii.) The number of Plerixafor (Mozobil) related serious adverse events (SAEs). iv.) The number of patients with Plerixafor (Mozobil) related serious adverse events (SAEs). As listed in the package insert, the most common adverse reactions (≥10%) during hematopoietic stem cell mobilization were: diarrhea (37%), nausea (34%), fatigue (27%), injection site reaction (34%), headache (22%), arthralgia (13%), dizziness (11%), and vomiting (10%). It should be noted that the majority of these occurred in patients also undergoing apheresis. Outcome Measure Time Frame: Primary Outcome Measure Time Frame: At baseline and at 8 hours post-Plerixafor (Mozobil) treatment Secondary Outcome Measures Time Frame: i.): Continuously for the first 30 minutes post-Plerixafor (Mozobil) treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. ii.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. iii.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. iv.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. Primary Study Goals: To determine whether Plerixafor (Mozobil) will mobilize CD117+ progenitor cells from the bone marrow in patients with chronic lung diseases on the lung transplant waiting list (versus normal controls). We will compare baseline counts of CD117+ cells with cell counts 8 hrs after Plerixafor to determine the efficacy of mobilization. The primary results will be used to determine the number of rounds of apheresis that may be required to isolate sufficient cells for reinfusion at later timepoints in a future study. Significance: If the investigators can mobilize a sufficient number of autologous CD117+ cells, they will eventually re-infuse them at the time of transplant to determine whether we can abrogate acute rejection following human lung transplantation (future study). The investigators believe these are safer than allogeneic stem cells as there is no risk for graft versus host disease (GVHD) with autologous cells. Hypothesis: These experiments should demonstrate the effectiveness of CD117+ stem cell mobilization from the bone marrow to the peripheral blood (PB) via CXCR4 antagonism (Plerixafor) and whether end-stage lung disease affects the ability to mobilize stem cells. Additionally, these results will be used to mathematically extrapolate approximately how many rounds of peripheral blood apheresis will be required to attain adequate stem cell numbers for clinical infusion (10e7) for a future study. Methods: Experiments will involve taking blood from consented patients awaiting lung transplantation (as well as normal controls) prior to Plerixafor (Mozobil) treatment (240mcg/kg subcutaneously) and then 8 hours after treatment as in Table 1. TABLE 1: Patient Category PB baseline analysis Plerixafor (Mozobil) Rx PB analysis 8hrs post-Rx Awaiting Tx (n=15, 5 chronic obstructive pulmonary disease (COPD), 5 Cystic Fibrosis (CF), and 5 Pulmonary Fibrosis (PF)) CD117 isolation/analysis by Flow Cytometry Yes - 240 mcg/kg CD117+ stem cell isolation/analysis by Flow Cytometry Normal Control (n=5) CD117 isolation/analysis by Flow Cytometry Yes - 240mcg/kg CD117+ stem cell isolation/analysis by Flow Cytometry More... »

URL

https://clinicaltrials.gov/show/NCT01916577

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The purpose of this study is to determine if the drug Plerixafor (Mozobil) can lead to clinically relevant efflux of CD117+ stem cells from the bone marrow to the peripheral blood of normal controls and patients awaiting lung transplantation. The investigator's hypothesis is that Plerixafor (Mozobil) will lead to significant mobilization of CD117+ stem cells to the peripheral blood.\n\nDetailed Description\nThe investigators have developed a new therapy utilizing a stem cell found in the bone marrow that is defined by cell surface expression of the protein \"cluster of differentiation antigen 117\" (CD117). Studies utilizing these stem cells in a mouse heart transplant model have demonstrated significantly improved survival of transplanted hearts, (as much as more than 5 times that seen with untreated heart transplants). In vitro studies in mice also show that these cells work to inhibit the immune system by inhibiting T cell activation/proliferation by both paracrine (primary) and contact-dependent (lesser) mechanisms. Importantly, these stem cells are taken from the intended transplant recipient (autologous) and since these cells are part of their own body normally (in small numbers); these cells are theoretically without risk to the patient. This is very different from other stem cell therapies, which are taken from the donor and as such put the patient at significant risk of developing potentially life-threatening immune reactions. Because the use of our own stem cells is potentially safe - the rapid study, development, and implementation of autologous CD117 stem cell (SC) therapy in human transplant patients is theoretically possible. Therefore, these cells have high impact potential for the field of tissue and organ transplantation as well as auto-immunity - to potentially improve tissue/cellular engraftment, decrease acute rejection, and/or to promote organ transplant tolerance (lack of rejection despite no concomitant immune-suppression). Prior to full clinical development (efficacy trials in humans), the next step is to develop a safe and efficacious means for obtaining relatively large quantities of these cells from potential human recipients. As bone marrow biopsy for cell capture is not without risk (especially to ill potential lung transplant recipients), the investigators propose to use Plerixafor (Mozobil), a CXC-chemokine receptor 4 (CXCR4)-inhibitor to cause efflux of bone marrow-derived CD117+ cells to the peripheral blood for capture by apheresis/positive selection. If successful, the next step will be to perform initial safety studies in human patients awaiting transplantation and normal controls (not a goal of this initial protocol however). These studies have the potential to lead to large-scale clinical efficacy trials and ultimate indication/implementation for human disease(s). Primary Outcome Measure: The number of circulating CD117+ cells per milliliter (ml) of peripheral blood at baseline and following Plerixafor (Mozobil) treatment (change in peripheral blood CD117+ cells per ml). Secondary Outcome Measures: i.) The number of Plerixafor (Mozobil) related adverse events (AEs). ii.) The number of patients with Plerixafor (Mozobil) related AEs iii.) The number of Plerixafor (Mozobil) related serious adverse events (SAEs). iv.) The number of patients with Plerixafor (Mozobil) related serious adverse events (SAEs). As listed in the package insert, the most common adverse reactions (\u226510%) during hematopoietic stem cell mobilization were: diarrhea (37%), nausea (34%), fatigue (27%), injection site reaction (34%), headache (22%), arthralgia (13%), dizziness (11%), and vomiting (10%). It should be noted that the majority of these occurred in patients also undergoing apheresis. Outcome Measure Time Frame: Primary Outcome Measure Time Frame: At baseline and at 8 hours post-Plerixafor (Mozobil) treatment Secondary Outcome Measures Time Frame: i.): Continuously for the first 30 minutes post-Plerixafor (Mozobil) treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. ii.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. iii.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. iv.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. Primary Study Goals: To determine whether Plerixafor (Mozobil) will mobilize CD117+ progenitor cells from the bone marrow in patients with chronic lung diseases on the lung transplant waiting list (versus normal controls). We will compare baseline counts of CD117+ cells with cell counts 8 hrs after Plerixafor to determine the efficacy of mobilization. The primary results will be used to determine the number of rounds of apheresis that may be required to isolate sufficient cells for reinfusion at later timepoints in a future study. Significance: If the investigators can mobilize a sufficient number of autologous CD117+ cells, they will eventually re-infuse them at the time of transplant to determine whether we can abrogate acute rejection following human lung transplantation (future study). The investigators believe these are safer than allogeneic stem cells as there is no risk for graft versus host disease (GVHD) with autologous cells. Hypothesis: These experiments should demonstrate the effectiveness of CD117+ stem cell mobilization from the bone marrow to the peripheral blood (PB) via CXCR4 antagonism (Plerixafor) and whether end-stage lung disease affects the ability to mobilize stem cells. Additionally, these results will be used to mathematically extrapolate approximately how many rounds of peripheral blood apheresis will be required to attain adequate stem cell numbers for clinical infusion (10e7) for a future study. Methods: Experiments will involve taking blood from consented patients awaiting lung transplantation (as well as normal controls) prior to Plerixafor (Mozobil) treatment (240mcg/kg subcutaneously) and then 8 hours after treatment as in Table 1. TABLE 1: Patient Category PB baseline analysis Plerixafor (Mozobil) Rx PB analysis 8hrs post-Rx Awaiting Tx (n=15, 5 chronic obstructive pulmonary disease (COPD), 5 Cystic Fibrosis (CF), and 5 Pulmonary Fibrosis (PF)) CD117 isolation/analysis by Flow Cytometry Yes - 240 mcg/kg CD117+ stem cell isolation/analysis by Flow Cytometry Normal Control (n=5) CD117 isolation/analysis by Flow Cytometry Yes - 240mcg/kg CD117+ stem cell isolation/analysis by Flow Cytometry", 
    "endDate": "2017-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01916577", 
    "keywords": [
      "lung transplantation", 
      "plerixafor", 
      "efflux", 
      "stem cell", 
      "bone marrow", 
      "peripheral blood", 
      "normal control", 
      "patient", 
      "mobilization", 
      "therapy", 
      "cell surface expression", 
      "protein", 
      "antigen", 
      "Studies utilizing", 
      "heart transplant", 
      "improved survival", 
      "transplanted heart", 
      "vitro study", 
      "mouse", 
      "cell work", 
      "immune system", 
      "T cell", 
      "paracrine", 
      "Transplant", 
      "cell", 
      "own body", 
      "small number", 
      "risk", 
      "stem cell therapy", 
      "Tissue Donor", 
      "significant risk", 
      "immune reaction", 
      "own stem cell", 
      "RAPID", 
      "development", 
      "implementation", 
      "transplant patient", 
      "high impact", 
      "tissue", 
      "organ transplantation", 
      "auto-immunity", 
      "engraftment", 
      "acute rejection", 
      "transplant tolerance", 
      "rejection", 
      "immune suppression", 
      "clinical development", 
      "efficacy trial", 
      "human", 
      "safe", 
      "large quantity", 
      "human recipient", 
      "bone marrow biopsy", 
      "lung transplant recipient", 
      "chemokine receptor", 
      "inhibitor", 
      "selection", 
      "safety study", 
      "human patient", 
      "transplantation", 
      "protocol", 
      "clinical efficacy", 
      "human disease", 
      "primary outcome measure", 
      "baseline", 
      "Secondary outcome measure", 
      "adverse event", 
      "serious adverse event", 
      "labeling", 
      "adverse reaction", 
      "Hematopoietic Stem Cell Mobilization", 
      "diarrhea", 
      "nausea", 
      "fatigue", 
      "injection site reaction", 
      "headache", 
      "Arthralgia", 
      "dizziness", 
      "vomiting", 
      "majority", 
      "Blood Component Removal", 
      "time frame", 
      "Organization and Administration", 
      "primary study", 
      "progenitor", 
      "chronic lung disease", 
      "lung transplant", 
      "list", 
      "Cell Count", 
      "efficacy", 
      "primary result", 
      "round", 
      "reinfusion", 
      "timepoints", 
      "future study", 
      "significance", 
      "sufficient number", 
      "graft host disease", 
      "Graft vs Host Disease", 
      "autologous cell", 
      "experiment", 
      "effectiveness", 
      "end-stage lung disease", 
      "stem cell number", 
      "infusion", 
      "method", 
      "blood", 
      "TX", 
      "chronic obstructive pulmonary disease", 
      "cystic fibrosis", 
      "pulmonary fibrosis", 
      "flow cytometry"
    ], 
    "name": "Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01916577"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00014.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.417555.7", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.241116.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.430503.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413085.b", 
        "type": "Organization"
      }
    ], 
    "startDate": "2013-08-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/bmt.2010.128", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013506949", 
          "https://doi.org/10.1038/bmt.2010.128"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/14653240903131640", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014197318"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.exphem.2008.10.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021967949"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01916577"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01916577'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01916577'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01916577'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01916577'


 

This table displays all metadata directly associated to this object as RDF triples.

147 TRIPLES      16 PREDICATES      133 URIs      121 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01916577 schema:about anzsrc-for:3048
2 schema:description The purpose of this study is to determine if the drug Plerixafor (Mozobil) can lead to clinically relevant efflux of CD117+ stem cells from the bone marrow to the peripheral blood of normal controls and patients awaiting lung transplantation. The investigator's hypothesis is that Plerixafor (Mozobil) will lead to significant mobilization of CD117+ stem cells to the peripheral blood. Detailed Description The investigators have developed a new therapy utilizing a stem cell found in the bone marrow that is defined by cell surface expression of the protein "cluster of differentiation antigen 117" (CD117). Studies utilizing these stem cells in a mouse heart transplant model have demonstrated significantly improved survival of transplanted hearts, (as much as more than 5 times that seen with untreated heart transplants). In vitro studies in mice also show that these cells work to inhibit the immune system by inhibiting T cell activation/proliferation by both paracrine (primary) and contact-dependent (lesser) mechanisms. Importantly, these stem cells are taken from the intended transplant recipient (autologous) and since these cells are part of their own body normally (in small numbers); these cells are theoretically without risk to the patient. This is very different from other stem cell therapies, which are taken from the donor and as such put the patient at significant risk of developing potentially life-threatening immune reactions. Because the use of our own stem cells is potentially safe - the rapid study, development, and implementation of autologous CD117 stem cell (SC) therapy in human transplant patients is theoretically possible. Therefore, these cells have high impact potential for the field of tissue and organ transplantation as well as auto-immunity - to potentially improve tissue/cellular engraftment, decrease acute rejection, and/or to promote organ transplant tolerance (lack of rejection despite no concomitant immune-suppression). Prior to full clinical development (efficacy trials in humans), the next step is to develop a safe and efficacious means for obtaining relatively large quantities of these cells from potential human recipients. As bone marrow biopsy for cell capture is not without risk (especially to ill potential lung transplant recipients), the investigators propose to use Plerixafor (Mozobil), a CXC-chemokine receptor 4 (CXCR4)-inhibitor to cause efflux of bone marrow-derived CD117+ cells to the peripheral blood for capture by apheresis/positive selection. If successful, the next step will be to perform initial safety studies in human patients awaiting transplantation and normal controls (not a goal of this initial protocol however). These studies have the potential to lead to large-scale clinical efficacy trials and ultimate indication/implementation for human disease(s). Primary Outcome Measure: The number of circulating CD117+ cells per milliliter (ml) of peripheral blood at baseline and following Plerixafor (Mozobil) treatment (change in peripheral blood CD117+ cells per ml). Secondary Outcome Measures: i.) The number of Plerixafor (Mozobil) related adverse events (AEs). ii.) The number of patients with Plerixafor (Mozobil) related AEs iii.) The number of Plerixafor (Mozobil) related serious adverse events (SAEs). iv.) The number of patients with Plerixafor (Mozobil) related serious adverse events (SAEs). As listed in the package insert, the most common adverse reactions (≥10%) during hematopoietic stem cell mobilization were: diarrhea (37%), nausea (34%), fatigue (27%), injection site reaction (34%), headache (22%), arthralgia (13%), dizziness (11%), and vomiting (10%). It should be noted that the majority of these occurred in patients also undergoing apheresis. Outcome Measure Time Frame: Primary Outcome Measure Time Frame: At baseline and at 8 hours post-Plerixafor (Mozobil) treatment Secondary Outcome Measures Time Frame: i.): Continuously for the first 30 minutes post-Plerixafor (Mozobil) treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. ii.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. iii.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. iv.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment. Primary Study Goals: To determine whether Plerixafor (Mozobil) will mobilize CD117+ progenitor cells from the bone marrow in patients with chronic lung diseases on the lung transplant waiting list (versus normal controls). We will compare baseline counts of CD117+ cells with cell counts 8 hrs after Plerixafor to determine the efficacy of mobilization. The primary results will be used to determine the number of rounds of apheresis that may be required to isolate sufficient cells for reinfusion at later timepoints in a future study. Significance: If the investigators can mobilize a sufficient number of autologous CD117+ cells, they will eventually re-infuse them at the time of transplant to determine whether we can abrogate acute rejection following human lung transplantation (future study). The investigators believe these are safer than allogeneic stem cells as there is no risk for graft versus host disease (GVHD) with autologous cells. Hypothesis: These experiments should demonstrate the effectiveness of CD117+ stem cell mobilization from the bone marrow to the peripheral blood (PB) via CXCR4 antagonism (Plerixafor) and whether end-stage lung disease affects the ability to mobilize stem cells. Additionally, these results will be used to mathematically extrapolate approximately how many rounds of peripheral blood apheresis will be required to attain adequate stem cell numbers for clinical infusion (10e7) for a future study. Methods: Experiments will involve taking blood from consented patients awaiting lung transplantation (as well as normal controls) prior to Plerixafor (Mozobil) treatment (240mcg/kg subcutaneously) and then 8 hours after treatment as in Table 1. TABLE 1: Patient Category PB baseline analysis Plerixafor (Mozobil) Rx PB analysis 8hrs post-Rx Awaiting Tx (n=15, 5 chronic obstructive pulmonary disease (COPD), 5 Cystic Fibrosis (CF), and 5 Pulmonary Fibrosis (PF)) CD117 isolation/analysis by Flow Cytometry Yes - 240 mcg/kg CD117+ stem cell isolation/analysis by Flow Cytometry Normal Control (n=5) CD117 isolation/analysis by Flow Cytometry Yes - 240mcg/kg CD117+ stem cell isolation/analysis by Flow Cytometry
3 schema:endDate 2017-12-01T00:00:00Z
4 schema:keywords Arthralgia
5 Blood Component Removal
6 Cell Count
7 Graft vs Host Disease
8 Hematopoietic Stem Cell Mobilization
9 Organization and Administration
10 RAPID
11 Secondary outcome measure
12 Studies utilizing
13 T cell
14 TX
15 Tissue Donor
16 Transplant
17 acute rejection
18 adverse event
19 adverse reaction
20 antigen
21 auto-immunity
22 autologous cell
23 baseline
24 blood
25 bone marrow
26 bone marrow biopsy
27 cell
28 cell surface expression
29 cell work
30 chemokine receptor
31 chronic lung disease
32 chronic obstructive pulmonary disease
33 clinical development
34 clinical efficacy
35 cystic fibrosis
36 development
37 diarrhea
38 dizziness
39 effectiveness
40 efficacy
41 efficacy trial
42 efflux
43 end-stage lung disease
44 engraftment
45 experiment
46 fatigue
47 flow cytometry
48 future study
49 graft host disease
50 headache
51 heart transplant
52 high impact
53 human
54 human disease
55 human patient
56 human recipient
57 immune reaction
58 immune suppression
59 immune system
60 implementation
61 improved survival
62 infusion
63 inhibitor
64 injection site reaction
65 labeling
66 large quantity
67 list
68 lung transplant
69 lung transplant recipient
70 lung transplantation
71 majority
72 method
73 mobilization
74 mouse
75 nausea
76 normal control
77 organ transplantation
78 own body
79 own stem cell
80 paracrine
81 patient
82 peripheral blood
83 plerixafor
84 primary outcome measure
85 primary result
86 primary study
87 progenitor
88 protein
89 protocol
90 pulmonary fibrosis
91 reinfusion
92 rejection
93 risk
94 round
95 safe
96 safety study
97 selection
98 serious adverse event
99 significance
100 significant risk
101 small number
102 stem cell
103 stem cell number
104 stem cell therapy
105 sufficient number
106 therapy
107 time frame
108 timepoints
109 tissue
110 transplant patient
111 transplant tolerance
112 transplantation
113 transplanted heart
114 vitro study
115 vomiting
116 schema:name Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
117 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01916577
118 schema:sdDatePublished 2019-03-07T15:25
119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
120 schema:sdPublisher N6f2b417531d94e5e871868b0a26139eb
121 schema:sponsor https://www.grid.ac/institutes/grid.241116.1
122 https://www.grid.ac/institutes/grid.413085.b
123 https://www.grid.ac/institutes/grid.417555.7
124 https://www.grid.ac/institutes/grid.430503.1
125 schema:startDate 2013-08-01T00:00:00Z
126 schema:subjectOf sg:pub.10.1038/bmt.2010.128
127 https://doi.org/10.1016/j.exphem.2008.10.017
128 https://doi.org/10.3109/14653240903131640
129 schema:url https://clinicaltrials.gov/show/NCT01916577
130 sgo:license sg:explorer/license/
131 sgo:sdDataset clinical_trials
132 rdf:type schema:MedicalStudy
133 N6f2b417531d94e5e871868b0a26139eb schema:name Springer Nature - SN SciGraph project
134 rdf:type schema:Organization
135 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
136 rdf:type schema:DefinedTerm
137 sg:pub.10.1038/bmt.2010.128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013506949
138 https://doi.org/10.1038/bmt.2010.128
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1016/j.exphem.2008.10.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021967949
141 rdf:type schema:CreativeWork
142 https://doi.org/10.3109/14653240903131640 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014197318
143 rdf:type schema:CreativeWork
144 https://www.grid.ac/institutes/grid.241116.1 schema:Organization
145 https://www.grid.ac/institutes/grid.413085.b schema:Organization
146 https://www.grid.ac/institutes/grid.417555.7 schema:Organization
147 https://www.grid.ac/institutes/grid.430503.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...